104例新生儿使用硫酸丁胺卡那霉素临床分析

胡又宁; 范颖; 王政力; 邓春

doi:10.13406/j.cnki.cyxb.002714

您当前的位置：

首页 >

文章列表页 >

104例新生儿使用硫酸丁胺卡那霉素临床分析

临床研究 | 更新时间：2022-06-24

- 104例新生儿使用硫酸丁胺卡那霉素临床分析
- Clinical analysis of amikacin sulfate used in 104 neonates
- 重庆医科大学学报 2022年47卷第5期页码：607-613
- 作者机构：
  
  重庆医科大学附属儿童医院新生儿科、国家儿童健康与疾病临床医学研究中心、儿童发育疾病研究教育部重点实验室、儿科学重庆市重点实验室，重庆　400014
- 作者简介：
  
  胡又宁，Email：958479747@qq.com，研究方向：新生儿抗生素使用。
  邓春，Email：dengcgcb@163.com。
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.002714
  中图分类号： R722.13
- 纸质出版日期：2022-05-28，
  
  收稿日期：2020-04-05，
扫描看全文
胡又宁, 范颖, 王政力, 等. 104例新生儿使用硫酸丁胺卡那霉素临床分析[J]. 重庆医科大学学报, 2022,47(5):607-613.

Youning Hu, Ying Fan, Zhengli Wang, et al. Clinical analysis of amikacin sulfate used in 104 neonates[J]. Journal of Shanxi Agricultural Sciences, 2022,47(5):607-613.
胡又宁, 范颖, 王政力, 等. 104例新生儿使用硫酸丁胺卡那霉素临床分析[J]. 重庆医科大学学报, 2022,47(5):607-613. DOI： 10.13406/j.cnki.cyxb.002714.

Youning Hu, Ying Fan, Zhengli Wang, et al. Clinical analysis of amikacin sulfate used in 104 neonates[J]. Journal of Shanxi Agricultural Sciences, 2022,47(5):607-613. DOI： 10.13406/j.cnki.cyxb.002714.

摘要

目的：

对重庆医科大学附属儿童医院新生儿病区静脉使用硫酸丁胺卡那霉素（阿米卡星）的患儿进行病例分析，总结使用阿米卡星的病原学依据、剂量、疗效、耳毒性、肾毒性，为临床用药提出指导。

方法：

回顾性分析重庆医科大学附属儿童医院新生儿病区2013年1月至2018年12月住院治疗的104例静脉使用阿米卡星的患儿病历资料，包括患儿的一般信息、病原学检查结果、主要诊断、阿米卡星使用情况、肾功能，并电话随访患儿出院后的听力情况。

结果：

本研究纳入静脉使用阿米卡星新生儿病例104例，平均胎龄为（32±4）周，出生体质量为1 395.00（1 131.25，2 190.00）g，血流感染、呼吸道感染、肠道感染、颅内感染是使用阿米卡星抗感染患儿主要感染部位。大多有病原学证据，包括血培养、痰培养、尿培养、分泌物培养等，培养结果主要为多重耐药肺炎克雷伯杆菌、大肠埃希菌。阿米卡星平均剂量为（14.97±1.94）mg/（kg·d），平均给药周期为（9.42±5.06）d。68例（65.4%）使用阿米卡星抗感染治疗后炎症指标和临床症状好转。使用过程中监测其肾功，采用多因素logistic回归分析，结果表明阿米卡星相关暴露变量与发生急性肾损伤之间无显著相关。出院后随访患儿生活中的听力情况，仅1例听力检查未通过，建议人工耳蜗治疗，其余患儿生活中听力无异常。

结论：

阿米卡星在新生儿病区多用于有多重耐药革兰阴性菌感染的患儿，使用剂量、时长、频次根据患儿疾病情况有差异，使用过程中应监测血药浓度，确保谷浓度及峰浓度在安全范围。其次，在肾毒性方面，阿米卡星相关暴露变量与发生急性肾损伤之间无显著相关。

Abstract

Objective

To analyze the cases who were given amikacin intravenously in the neonatal ward of Children's Hospital of Chongqing Medical University and to summarize the etiological basis

dose

efficacy

ototoxicity

and nephrotoxicity of amikacin for providing guidance for clinical medication of amikacin.

Methods

A retrospective study described the clinical features of 104 neonates with amikacin intravenously admitted to the Neonatal Ward of the Children's Hospital of Chongqing Medical University from January 2013 to December 2018

including general information

etiological examination results

main diagnosis

amikacin usage

renal function

and telephone follow-up of their hearing situation after discharge.

Results

Totally 104 neonates given amikacin intravenously were included in this study

with an average gestational age of (32±4) weeks

and a median birth weight of 1 395.00 (1 131.25

2 190.00) g. Bloodstream infections

respiratory tract infections

intestinal infections

and intracranial infections were the main infection sites of patients treated with amikacin. Most of them had pathogenic evidence

including blood culture

sputum culture

urine culture

secretion culture

etc. The culture results were mainly multidrug-resistant Klebsiella pneumoniae and Escherichia coli. The average dose of amikacin was (14.97±1.94) mg/ (kg·d)

and the average administration duration was (9.42±5.06) days. A total of 68 cases (65.4%) showed improvement in inflammation and clinical symptoms after treatment with amikacin. The renal function was monitored in use

and multivariate logistic regression analy sis was used. The results showed that there was no significant correlation between amikacin-related exposure variables and the occurrence of acute kidney injury. After discharge

the children's hearing situation was followed up. Only one case failed the hearing test and cochlear implantation was recommended. The remaining children had no abnormal hearing in life.

Conclusion

Amikacin is mostly used in neonatal wards for patients with multi-drug resistant gram-negative bacteria infection. The dosage using

duration and frequency of amikacin are different according to the disease situation of the neonates. The plasma concentration should be monitored to ensure that trough concentration and peak concentration are within the safe range. In addition

in terms of nephrotoxicity

there is no significant correlation between amikacin-related exposure variables and the occurrence of acute kidney injury.

关键词

阿米卡星新生儿耳毒性肾毒性

Keywords

amikacinneonateototoxicitynephrotoxicity

references

Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis[J]. Lancet, 2015, 385(9966): 430-440.

中华医学会儿科学分会新生儿学组, 中国医师协会新生儿科医师分会感染专业委员会. 新生儿败血症诊断及治疗专家共识(2019年版)[J]. 中华儿科杂志, 2019, 57(4): 252-257.

The SubspeciaLty Group of NeonatoLogy, the Society of Pediatric. Expert consensus on the diagnosis and management of neonataL sepsis (version 2019)[J]. Chin J Pediatr, 2019, 57(4): 252-257.

贾忠兰, 毕福玲, 张彩明. 新生儿败血症病原菌分布及耐药性分析[J]. 中华医院感染学杂志, 2017, 27(1): 197-200.

Jia ZL, Bi FL, Zhang CM. Distribution and drug resistance of pathogens isolated from neonates with septicemia[J]. Chin J Nosocomiology, 2017, 27(1): 197-200.

Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge[J]. Lancet, 2016, 387(10014): 168-175.

Tsai MH, Chu SM, Hsu JF, et al. Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU[J]. Pediatrics, 2014, 133(2): e322-e329.

Ho J, Tambyah PA, Paterson DL. Multiresistant Gram-negative infections: a global perspective[J]. Curr Opin Infect Dis, 2010, 23(6): 546-553.

Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity[J]. Hear Res, 2011, 281(1/2): 28-37.

Avent ML, Rogers BA, Cheng AC, et al. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity[J]. Intern Med J, 2011, 41(6): 441-449.

Young T. Aminoglycoside therapy in neonates: with particular reference to gentamicin[J]. NeoReviews, 2002, 3(12), 243-248.

Kent A, Turner MA, Sharland M, et al. Aminoglycoside toxicity in neonates: something to worry about?[J]. Expert Rev Anti Infect Ther, 2014, 12(3): 319-331.

Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates[J]. Clin Pharmacokinet, 2009, 48(2): 71-88.

Swan SK. Aminoglycoside nephrotoxicity[J]. Semin Nephrol, 1997, 17(1): 27-33.

Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance[J]. Clin Microbiol Infect, 2012, 18(3): 268-281.

陈子衿, 徐珍娥. 新生儿急性肾损伤研究进展[J]. 儿科药学杂志, 2019, 25(5): 62-65.

Chen ZJ, Xu ZE. Process in neonatal acute kidney injury[J]. J Pediatr Pharm, 2019, 25(5): 62-65.

Ivády B, Kenesei é, Tóth-Heyn P, et al. Factors influencing antimicrobial resistance and outcome of Gram-negative bloodstream infections in children[J]. Infection, 2016, 44(3): 309-321.

刘艳, 马丹娟, 黄瑞玉, 等. 新生儿重症监护病房多重耐药革兰阴性菌血流感染危险因素回归分析[J]. 检验医学与临床, 2019, 16(6): 783-785, 789.

Liu Y, Ma DJ, Huang RY, et al. Regression analysis of risk factors of multidrug-resistant gram-negative bacterial blood infection in neonatal intensive care unit[J]. Lab Med Clin, 2019, 16(6): 783-785, 789.

Abe R, Oda S, Sadahiro T, et al. Gram-negative bacteremia induces greater magnitude of inflammatory response than Gram-positive bacteremia[J]. Crit Care, 2010, 14(2): R27.

Yusef D, Shalakhti T, Awad S, et al. Clinical characteristics and epidemiology of Sepsis in the neonatal intensive care unit in the era of multi-drug resistant organisms: a retrospective review[J]. Pediatr Neonatol, 2018, 59(1): 35-41.

Abdel-Bari A, Mokhtar MS, Sabry NA, et al. Once versus individualized multiple daily dosing of aminoglycosides in critically ill patients[J]. Saudi Pharm J, 2011, 19(1): 9-17.

Pagkalis S, Mantadakis E, Mavros MN, et al. Pharmacological considerations for the proper clinical use of aminoglycosides[J]. Drugs, 2011, 71(17): 2277-2294.

Nestaas E, Bangstad HJ, Sandvik L, et al. Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis[J]. Arch Dis Child Fetal Neonatal Ed, 2005, 90(4): F294-F300.

Vucicevic K, Rakonjac Z, Miljkovic B, et al. Pharmacokinetic variability of amikacin after once-daily and twice-daily dosing regimen in full-term neonates[J]. J Pharmacol Sci, 2014, 124(2): 138-143.

de Cock RFW, Allegaert K, Schreuder MF, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance[J]. Clin Pharmacokinet, 2012, 51(2): 105-117.

Smits A, de Cock RFW, Allegaert K, et al. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice[J]. Antimicrob Agents Chemother, 2015, 59(10): 6344-6351.

Sherwin CMT, Svahn S, van der Linden A, et al. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis[J]. Eur J Clin Pharmacol, 2009, 65(7): 705-713.

American Academy of Pediatrics. 2006 red book: report of the committee on infectious diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2006.

Ducher M, Maire P, Cerutti C, et al. Renal elimination of amikacin and the aging process[J]. Clin Pharmacokinet, 2001, 40(12): 947-953.

Serio AW, Keepers T, Andrews L, et al. Aminoglycoside revival: review of a historically important class of antimicrobials undergoing rejuvenation[J]. EcoSal Plus, 2018, 8(1): ESP-0002-2018.

Alaee E, Sirati M, Taziki MH, et al. Risk factors for sensorineural hearing loss among high-risk infants in golestan Province, Iran in 2010-2011[J]. Iran Red Crescent Med J, 2015, 17(12): e20419.

Endo A, Nemoto A, Hanawa K, et al. Relationship between amikacin blood concentration and ototoxicity in low birth weight infants[J]. J Infect Chemother, 2019, 25(1): 17-21.

Cone-Wesson B, Vohr BR, Sininger YS, et al. Identification of neonatal hearing impairment: infants with hearing loss[J]. Ear Hear, 2000, 21(5): 488-507.

Zimmerman E, Lahav A. Ototoxicity in preterm infants: effects of genetics, aminoglycosides, and loud environmental noise[J]. J Perinatol, 2013, 33(1): 3-8.

Luft FC. Clinical significance of renal changes engendered by aminoglycosides in man[J]. J Antimicrob Chemother, 1984, 13(Suppl A): 23-30.

Gallagher RM, Kirkham JJ, Mason JR, et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool[J]. PLoS One, 2011, 6(12): e28096.

Cuzzolin L, Fanos V, Pinna B, et al. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions[J]. Pediatr Nephrol, 2006, 21(7): 931-938.

Yao L, Zhang JW, Chen B, et al. Mechanisms and pharmacokinetic/pharmacodynamic profiles underlying the low nephrotoxicity and ototoxicity of etimicin[J]. Acta Pharmacol Sin, 2020, 41(6): 866-878.

Fuchs A, Zimmermann L, Bickle Graz M, et al. Gentamicin exposure and sensorineural hearing loss in preterm infants[J]. PLoS One, 2016, 11(7): e0158806.

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

治疗剂量阿米卡星在新生豚鼠药代动力学及耳毒性研究

新生儿呼吸窘迫综合征临床路径应用评价

2010至2014年我院新生儿肺炎主要病原菌分布及耐药性变迁

新生儿肠道双歧杆菌与其婴儿期腹泻关系的研究